WellBeing International

WBI Studies Repository
2003

Pain and Distress Associated with Polyclonal Antibody
Production: Discussion and Recommendations
The Humane Society of the United States

Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/ari_rp
Part of the Animal Experimentation and Research Commons, Animal Studies Commons, and the
Design of Experiments and Sample Surveys Commons

Recommended Citation
The Humane Society of the United States, "Pain and Distress Associated with Polyclonal Antibody
Production: Discussion and Recommendations" (2003). ANIMAL RESEARCH. 1.
https://www.wellbeingintlstudiesrepository.org/ari_rp/1

This material is brought to you for free and open access
by WellBeing International. It has been accepted for
inclusion by an authorized administrator of the WBI
Studies Repository. For more information, please contact
wbisr-info@wellbeingintl.org.

Pain and Distress
Associated with Polyclonal
Antibody Production

Discussion
and
Recommendations

Promoting the protection of all animals

Pain and Distress
Associated with Polyclonal
Antibody Production

Discussion
and
Recommendations

Promoting the protection of all animals

Executive Summary
The Humane Society of the United States
(HSUS) held a workshop in August 2002
in order to develop recommendations for
minimizing pain and distress associated
with polyclonal antibody (Pab) production.
A small group of experts in the fields of
antibody production, animal welfare, in vitro
alternatives, and/or regulatory compliance
participated in the roundtable discussion.
The workshop was a scientifically based
meeting, and recommendations were based
on the extensive experience of the workshop
participants as well as published literature
regarding the relevant issues.
Participants recognized that insufficient
attention has been paid to animal welfare
aspects of Pab production, in part because
this technique typically is a small part of larger
research projects and is not, per se, directly
related to the hypothesis being investigated.
This lack of attention, as well as the pain
and distress associated with Pab production,
has led to our focus on this specific issue.
Additionally, information in the published
literature regarding Pab production varies
greatly, further prompting the need to
determine and harmonize recommendations.
Antibodies are produced by injecting an
adjuvant (antigen) into the animal (human
or nonhuman), thereby eliciting an antibody
response by the immune system. The
challenge involved in Pab production is to
obtain high antibody yield while minimizing
pain and distress to the animals. Several
aspects of Pab production were considered
by the group, including the determination
of appropriate adjuvants, optimal volume
of adjuvant per species, and optimal route
of immunization; use of booster injections;
consideration of available alternatives; and
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measurement of animal welfare. Each
of these topics was considered in regard
to minimization of pain and distress,
and recommendations were generated.
The participants also briefly discussed
monoclonal antibody (Mab) production
and corresponding alternatives.
The workshop resulted in both general
and specific recommendations. General
recommendations addressed outsourcing
to Pab suppliers; increasing and improving
training; increasing consideration of
alternative production techniques; improving
pain and distress assessment via score sheets;
harmonizing guidelines; keeping abreast
of and incorporating recent developments;
minimizing the number of animals used
when possible; and including relevant Pab
production information in published papers.
Some of the specific recommendations
addressed were using the chicken egg yolk
technique as a refinement and reduction
procedure; choosing an adjuvant that
produces high antibody yield while
minimizing pain and distress; considering
the use of Freund’s complete adjuvant (FCA)
for the first injection; using the smallest
volume of adjuvant possible; and determining
appropriate use of booster injections. Finally,
areas in which additional research is needed
were discussed—such as proper pain and
distress assessment, formulation of new
adjuvants, and examination of the roles
that pain and enrichment may play in Pab
production. The recommendations from
this workshop will be widely distributed
in order to press the debate on this issue
and to increase attention to the pain and
distress associated with Pab production.

3

Introduction
The Humane Society of the United States
(HSUS) hosted a workshop on refinements
to polyclonal antibody (Pab) production in
conjunction with the Fourth World Congress
on Alternatives and Animal Use in the Life
Sciences in New Orleans, Louisiana, on August
11, 2002. A small group of experts in the
fields of antibody production, animal welfare,
in vitro alternatives, and the regulation of
the use of animals for experimental and
other scientific purposes participated
in a roundtable discussion of Pab and
monoclonal antibody (Mab) production;
their recommendations are presented here.
Coenraad Hendriksen, D.V.M., Ph.D.,
an expert in vaccine and biologicals
quality control, chaired the workshop. The
recommendations made in this document
were based on the extensive experience
of the workshop participants as well as
on relevant published literature. See
Appendix I for a list of participants.
Dissemination of information within the
scientific community regarding good practices
and techniques is essential to reduce pain
and distress in animal research. The HSUS,
through its Pain & Distress Initiative, works
toward the goal of eliminating animal
pain and distress in research and testing.
Conducting technical workshops and
disseminating the resulting information is one
aspect of this initiative. The first such HSUS
workshop addressed the use of animals in
toxicity testing (see www.hsus.org/ace/11447).
The main aim of the antibody workshop
was to review the current “state of the art”
and develop recommendations on techniques
involved in the production of Pabs. Pab
production is typically not the primary
focus or goal of research projects, but only
comprises one step in the process. Available
information on animal welfare aspects of Pab
production tends to be relatively generic or
consists more of anecdotal reports than careful
scientific studies. This workshop was convened
to identify and resolve conflicts regarding
animal welfare recommendations and to
suggest topics for further investigation
and clarification.
Additional aims of the workshop were to
identify components of “best practices” and
The Humane Society of the United States

encourage examination of the inconsistencies
in the various published guidelines regarding
Pab production, as well as to encourage the
U.S. National Institutes of Health to allocate
funding to research unanswered questions.
Overall, the workshop sought to refine
procedures so that less pain and suffering
is caused during Pab production and
optimum immune responses are obtained.
The Canadian Council on Animal
Care (CCAC) produced a comprehensive
monograph on the subject of antibody
production in 2002 (www.ccac.ca/english/gdlines/
antibody/antibody.pdf ). The HSUS workshop
did not seek to replicate or replace the
CCAC document, but sought to complement
it and discuss specific areas in greater depth.
However, there were instances in which
workshop participants questioned aspects of
the CCAC guidelines, further supporting the
need for increased examination of these issues.

Polyclonal Antibody
Production: Overview
In the laboratory, antibodies are produced
by injecting an immunogen (a chemical
that is foreign to that species, such as a
protein or glycoprotein from another species
or microorganism) usually in combination
with an adjuvant (antigen) into the animal,
stimulating an antibody response by the
immune system. Mabs are produced by cells
that are derived from a single clone of an
antibody-producing cell (B cell or plasma cell);
they produce identical antibodies that all react
to the same site (epitope) on the immunogen
or a cross-reacting antigen. In contrast,
Pabs are derived from many different clones,
producing many sets of antibodies that will
bind to various sites on the antigen; therefore,
they have decreased specificity in comparison
with Mabs, but a range of differing avidities
(i.e., strength of binding).
Rabbits are the most commonly used
species in laboratory Pab production largely
because they are easy to bleed, house, and
handle and their bodies can take adequate
volumes of serum. However, mice, rats,
guinea pigs, and large mammals such as
horses, sheep, and goats are used for antibody
production as well (Schade et al., 1996).
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Chickens are also used for this purpose
(producing immunoglobulin Y [IgY] in egg
yolk), but the procedures differ from those
used in mammals, as will be discussed later.
In addition to housing and care issues,
there are two stages in the production of
Pabs that raise animal welfare concerns:
the immunization procedure and the bleeding
of the animal. The antigen challenge, part
of the immunization procedure, is to obtain
high antibody yield of good quality while
minimizing pain and distress to the animals.
In this document, we focus primarily on
immunization procedures, including
determination of appropriate adjuvant,
optimal volume of adjuvant per species,
optimal route of immunization, permissibility
of booster injections, and measurement
of animal welfare. In the workshop, each
of these topics was considered in relation
to minimizing any pain or distress. The
participants also discussed Mab production
as well as alternatives to Mab and Pab
production. The workshop recommendations
are given below. For information regarding
bleeding protocols and determination of
appropriate species, please refer to the
CCAC guidelines on antibody production
(2002) and Leenaars et al. (1999).

Recommendations
Require Appropriate Training
■

Recommendation: Only experienced
personnel should be allowed to
conduct antibody production.

Personnel should be properly trained in
all relevant aspects of antibody production,
including: preparation of immunogenadjuvant mixture (emulsion); preparation of
noninfective injectates; injection technique;
bleeding; assessment of welfare (such as any
pain and distress); and, finally, any subsequent
animal care. Causing minimal animal pain
and distress during the process of producing
antibodies is an important task and requires
a well-trained staff.

6

Determine Needs
and Consider Alternatives
■

Recommendation: Determine on a caseby-case basis when it is more appropriate
to use Mabs instead of Pabs.

Investigators should carefully determine
whether Pabs or Mabs are necessary in
order to meet the needs of the research
or application (e.g., for diagnostic testing).
If it is determined that Mabs would be
preferable over (or equivalent to) Pabs,
then Mab production should be done via
in vitro techniques. In vitro Mab production
still involves mice in the initial immunization
stage, but in vitro techniques can be used for
the propagation and harvesting of Mabs from
the hybridoma—therefore causing significantly
less pain and distress in comparison with
the use of mice for the entire production
process (known as the ascites method). For
additional information on Mab production,
see page 10.
■

Recommendation: Institutions
should utilize the chicken egg
yolk (IgY) technique for Pab
production when possible.

Pabs can be obtained from IgY in higher
quantities compared to mammals such as
rabbits. There are various animal welfare
advantages to using this technique. For
example, since significantly larger quantities
of antibodies can be produced per animal,
this technique requires fewer animals overall
(reduction). This technique is also considered
to be a refinement method because no
bleeding of the chicken is necessary, as it
is with the use of other species; therefore,
the elimination of one of two invasive steps
leads to a substantial reduction in distress
when hens are used (Schade et al., 1996).
Additionally, as was indicated by Gassmann
et al. (1990) in regard to the use of Freund’s
complete adjuvant (FCA) in chickens,
immunization sites in chickens may not
be associated with marked local inflammatory
responses as is the case in mammals.
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There was some speculation as to why
the IgY technique is not more widely used,
given that it addresses both reduction and
refinement. One factor may be that an
appropriate facility for housing chickens is
necessary and institutions may not have such
facilities. Scientists may be hesitant to use
procedures that are different from those they
are used to and they may lack training in the
technique. It typically takes 24–72 hours for
the IgY antibodies to bind, and this may be
a technical barrier (immunoglobulin G [IgG]
can take less time, but no published studies
have compared IgG and IgY in regard to
optimal binding time). Finally, IgY may not
be acceptable in cases where the antibody
may be used in an in vitro mammalian culture.
There are, however, benefits to the use
of the chicken egg yolk technique beyond
animal welfare concerns that are important
to consider. For example, a hen produces
10 times more IgY in one month than
comparable IgG obtained from a rabbit.
Additionally, the hen’s immune system
“has properties favorable for producing
antibodies against highly preserved
mammalian antigens” (Schade et al., 2001),
which may be caused by phylogenetic
differences between avian and mammalian
species; therefore, IgY antibodies are
particularly advantageous when antibodies
to highly conserved sites or epitopes are
required. Finally, false positive reactions in
certain immunochemical assays are unlikely
(Schade et al., 1996). There is sufficient
evidence, therefore, that IgY meets both
scientific needs and animal welfare concerns.
For additional information, the European
Centre for the Validation of Alternative
Methods published a report and
recommendations on IgY (Schade et al.,
1996; http://altweb.jhsph.edu/publications/
ECVAM/ecvam21.htm), and Schade et al.
(2001) published a book on the topic.
These publications include information
on appropriate housing of chickens,
immunization techniques (i.e., type
of adjuvant, dose, and volume), and
isolation and purification methods.
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Outsourcing
■

Recommendation: Investigators should
utilize qualified commercial suppliers
when possible.

The difficulty of producing Pabs and the level
of expertise needed for such production were
discussed. The use of reputable and qualified
commercial suppliers experienced in the
development and use of humane production
procedures was recommended, but with
certain stipulations. One incentive for using
commercial suppliers is that Pabs are less
expensive when one considers the real costs
of animal care, staff time, and equipment
needed for Pab production. In the United
States, investigators should be aware that
if their institution has an assurance on file
with the Public Health Service (PHS), then
the antibody supplier must also have PHS
assurance. Workshop participants also
recommend that these qualified commercial
suppliers be accredited by the Association for
Assessment and Accreditation of Laboratory
Animal Care International.
Appendix II lists websites with information
on antibody suppliers. Listing of specific
companies in this appendix in no way
signifies endorsement of these companies
by The HSUS.

Routes of Injection
■

Recommendation: Intramuscular
(IM), intraperitoneal (IP), intrasplenic,
intravenous (IV), and footpad
injections should be discouraged.

The workshop participants agreed that there
is sufficient evidence, both in the published
literature and from their own experience,
that IM, IP, intrasplenic, and footpad routes
of injection result in increased pain and distress
and increased risk of lesions, and should
therefore be discouraged. IV injection, which
is not often used, can lead to an anaphylactic
response. If these routes are used, strong
scientific justification should be provided.
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Diligent care should be performed
for an aseptic, noncontaminating injection.
Preparation of the injection site that
includes the removal of fur and a wipe
with an appropriate antiseptic (povidine,
chlorhexidine) is normally sufficient. For
intradermal sites, the hair should be clipped;
this may not always be necessary for other
routes of injection. For additional information
regarding preparation of the injection site,
please refer to Leenaars et al. (1999).
Adjuvants that can be coadministered
with antigens orally and nasally are new
developments (Eriksson & Holmgren,
2002; Foss & Murtaugh, 2000); researchers
are encouraged to monitor the emerging
literature in this area, as oral and nasal routes
of administration may produce an appropriate
antibody response and may be preferred in
regard to animal welfare. A major problem is
that a local immunity (IgA) response is elicited
rather than a humoral (IgG) response.
■

Recommendation: Subcutaneous (SC)
and intradermal (ID) were considered to
be acceptable routes of injection. However,
additional research is needed in order
to determine whether either SC or ID
is the preferable injection route in
regard to animal welfare.

injection of FCA, the rabbits do not show signs
of pain. When the ID route is used, the skin
on the rabbits’ backs is very sensitive and the
animals twitch even when not being touched,
suggesting that the lesions cause discomfort
in terms of pain or itching. The rabbits also
appear to have a stronger aversive reaction
to being handled.
During this discussion, it was pointed out
that SC injections may appear to be acceptable
because no lesions are visible, but appearances
may deceive. The manifestation of draining
lesions may be upsetting to the personnel
working with the animals and may therefore
prevent them from using ID injections.
The use of the ID route seems to be
more common in the United States while
SC appears to be preferred in Europe. The
CCAC guidelines on antibody production
(2002) discourage the use of ID injection
for small animals such as mice and rats.
The participants generally agreed with this
recommendation. In any event, it would
be very difficult to ensure that an injection
is an ID route in thin-skinned animals
such as mice and rats.

Pain and Distress Assessment
■

Although SC and ID were the recommended
injection routes, there was discussion
concerning which is the best in terms of
animal welfare. For example, one participant
argued that SC injections cause abscesses and
more granulomas when compared with ID
injections. It was further argued that ID is the
preferred route because the resulting lesions
are readily visible and can be easily treated
and monitored. The participant conducted
a study (unpublished) that examined the
ID route by measuring white cell counts,
inflammatory response, and body
temperature, and used an imaging technique
(behavior was not examined). Following
this study, the participant feels confident
in the use of ID injections.
A second participant disagreed that
the ID route is preferable and reported fewer
problems with the SC method in terms of
animal welfare. For example, on palpation
of the subcutaneous nodules due to SC
8

Recommendation: Daily observations
should be made by properly trained
personnel in order to assess pain
and distress during Pab production,
and if necessary, adjustments to the
protocol should be made accordingly.

Pain is an unnecessary and unwanted side
effect in immunization procedures (Amyx,
1987), and steps can be taken to minimize
the pain and distress associated with these
procedures. The use of score sheets was
discussed as a useful approach to pain and
distress assessment (Morton, 2000). These
sheets could include categories such as activity
level, gait, hair coat, appetite, grooming,
pruritis, scratching, signs of inflammation,
twitching of skin, posture (lying stretched out
or not), and the presence of lesions. Again,
proper training of personnel is an important
factor. Appendix III is an example of a score
sheet created and used by the University
of Birmingham, United Kingdom.
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Welfare assessments of animals used
for Pab production should occur in a setting
in which the animals can move about freely
so that clinical signs of lameness can be
seen, especially if an IM injection site is used.
Lameness is obvious when animals are kept in
pens where they can normally move around
and express their natural behaviors. Rabbits
housed in a standard rabbit cage may appear
to be fine; only when they are placed in a run
may it be noticeable that they do not move
or interact socially to the extent that control
animals do. One participant pointed out,
however, that a run may be unfamiliar and
intimidating to laboratory rabbits; therefore,
placement in a run may not be useful for
welfare assessment. In this case, the rabbits
should be encouraged to move within
their home cages (without causing stress
to the animals), and reluctance to move
can be interpreted as abnormal.
In regard to pain and distress relief,
treatment of dermal reactions under
veterinary direction is recommended and
poses no interference with the production
of Pabs. For example, topical preparations
with and without antibiotics, topical
antibiotics combined with topical cortisone
that are minimally absorbed, and topical
anesthetics can each be effective.
Overall, it was agreed that pain and
distress associated with Pab production
is a topic that needs closer examination
and more data.

mineral salts (such as aluminum hydroxide),
microbial products (such as glycopeptides),
surfactants (such as liposomes), cytokines, and
others. As a result of this range of available
adjuvants and in the case of unknown
immunogens, pilot studies (with the use of
score sheets) are one means of determining
which adjuvant to use. Institutional Animal
Care and Use Committees (IACUCs) should
carefully scrutinize the choice of adjuvant
when assessing protocols that involve Pab
production, request actual data (e.g., titer,
class of antibody, avidity of antibody) from
the investigator, and require animal care staff
to monitor the animals and report back to
the IACUC regarding their condition. Overall,
an informed choice has to be made based on
the nature of the immunogen and the class
of immunoglobulin required to maximize
the antibody yield and to minimize the
welfare cost.
In addition to determining which adjuvant
to use, the amount of mycobacteria, the
molecular length (or molecular weight) of
the oil component, and the adjuvant/antigen
ratio can lead to different scientific and
welfare outcomes with different batches of
the same adjuvant. This again highlights the
importance of keeping up with the literature,
seeking expert advice, performing pilot
studies, and developing experience and
expertise among animal care staff and
those carrying out the procedure.
■

Adjuvants
■

Recommendation: The chosen adjuvant
should ideally induce high antibody
titers in serum and/or egg yolk while
minimizing pain and distress. Adjuvant
choice should be carefully determined
and pilot studies are suggested as one
way to determine the best adjuvant
for a particular immunogen or
class of antigens.

There is an abundance of published
information on the different adjuvants
available, and there are many conflicting
claims. The various available adjuvants include
FCA (discussed further below), incomplete
Freund’s adjuvant (IFA), Ribi®, Titremax®,
The Humane Society of the United States

Recommendation: FCA may not be as
problematic with regard to pain and
distress as has been suggested and may
have advantages over other adjuvants
when used properly (more details
regarding proper use follow). However,
when using FCA, it is crucial that the
volume used be minimized (based on
route of injection and animal species),
the sample for injection is properly
prepared, and the administration
competently performed. Under no
circumstances should an animal be
given a second injection of FCA.

There is broad agreement that FCA gives a
strong antibody response in comparison with
most of the other adjuvants; this is why FCA
is often the adjuvant of choice. However, there
9

has been much debate over the use of FCA
due to reports of resulting local inflammatory
response (Amyx, 1987; Broderson, 1989;
and others). Consideration of scientific needs
and animal welfare must be done with caution
and be carefully balanced in order to minimize
pain and distress while also minimizing
the numbers of animals used.
It has been suggested that much of the
concern regarding adverse FCA reactions
involved studies of humans with prior
sensitivity to mycobacteria, such as tuberculosis
(Chapel & August, 1976). Any mammal with
prior sensitivity will react very strongly to FCA,
and this is the reason FCA should not be used
for booster immunizations. A booster injection
should not be necessary when using FCA
because the FCA titer does not plateau for six
weeks (much later than most other adjuvants).
However, if a booster is determined to
be necessary, IFA or any other adjuvant
not including mycobacteria can be used.
The volume of FCA injected per site
is a critical factor influencing the levels of
pain and distress and should be given careful
consideration (Amyx, 1987; Halliday et al.,
2000; also see recommendation regarding
volumes below). It is also important to
note that the majority of published studies
that used FCA to specifically induce an
inflammatory response involved injection
of FCA into the hind paw—an injection
route that is not recommended.
Again, anecdotal reports and the few
scientific reports investigating FCA use give
conflicting results. In this context it must be
realized that there are differences between the
protocols and emulsions used. This is another
area that needs to be examined closely.

Cytokines
■

Recommendation: If cytokines are
used as adjuvants, only small levels
are necessary for an adequate
antibody response, and this will
also avoid adverse effects.

The use of cytokines (proteins that affect
immune response) as adjuvants is expensive
and, therefore, uncommon. However, when
used, cytokine adjuvants typically result in
a rapid high titer followed by a rapid drop
10

in titer. The response is species-specific, and
an animal’s reaction and pathology depend
on the concentration of cytokines. Therefore,
when using cytokine adjuvants, the animals
should be closely monitored and pilot studies
are recommended.

Volume and Number of Sites
■

Recommendation: Regardless of the
adjuvant chosen, the smallest volume
possible that produces an adequate
antibody response should be used. It
is recommended that very small volumes
be injected into multiple sites for
an enhanced antibody response.

Participants agreed that the route of injection
and the volume used are equally important
as the actual type of adjuvant used in
minimizing pain and distress associated
with the procedure. It was agreed by most
participants that the greater the number
of sites, the greater the antibody response.
Larger volumes per site may lead to
increased ulceration and welfare problems;
therefore, small volumes are preferable and
recommended (ANZCCART, 1998). The
CCAC guidelines on antibody production
(2002) specify recommended volumes for
different species. It should be noted that one
participant expressed concern with the use
of greater than four injection sites (which,
properly sited, will drain to the four major
lymph node groups) on scientific and
welfare grounds.
Please see Morton et al. (2001)
and Diehl et al. (2001) for additional
information regarding this issue.

Additional
Recommendations
Harmonization of guidelines: There are
many guidelines regarding Pab production
available from various organizations and
agencies, and some of these conflict. We
suggest that appropriate organizations
hold a workshop of all stakeholders in
order to address harmonization around
best contemporary practice. Inconsistencies
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should be examined and reasons for
disagreements or “special needs”
should be addressed and understood.
Choice of species: For information
regarding choice of species for Pab
production, see Leenaars et al. (1999)
and CCAC (2002).

Areas for
Further Research:
Pab Production
This lengthy discussion of Pab production
resulted in as many questions as there
were answers. The following is a list of areas
that were determined to need additional
research and examination (in order of
priority/importance). We emphasize that
such research should, whenever possible,
be “piggybacked” onto existing work in
order to avoid the use of additional animals.
1. Welfare and pain and distress
assessments: Such assessments are
severely underrepresented in the
literature and should be a major area
of concern. Species-specific information
regarding welfare and pain and distress
is needed—including behavioral data
which is often either discounted or
ignored—particularly in the context
of pair- and group-housing situations.
2. Alternatives to adjuvants: The first
question should always be: Do I
need an adjuvant? Based on the
characteristics of the antigen, in many
cases this question can be answered
without performing a pilot study. A
means of creating an immune response
without using some of the current
adjuvants should be studied, given
that adjuvants are responsible for
much of the pain and distress
associated with antibody production.
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3. New adjuvants: Additional research
on new adjuvants and immunization
methods (including DNA vaccines) is
necessary as such adjuvants may result
in decreased pain and distress.
4. Pain: It should be determined what
role pain actually plays in the antibody
response. It is possible that if pain is
decreased, antibody production would
increase—this would lead not only to
refinement through decreased pain
and distress, but reduction in the
number of animals needed in
order to meet scientific needs.
5. Mycobacteria: The effects of varying
amounts of mycobacteria in adjuvants
should be examined in order to
determine if certain mycobacteria
levels are preferable in regard to
animal welfare.
6. Injections: ID versus SC routes
of injection should be examined
(particularly in regard to behavior and
antibody yield) in order to determine
the optimal injection route from
the animal welfare perspective.
7. Enrichment: It should be determined
whether cage enrichment and group
housing would simplify the recognition
and management of welfare problems
as well as improve production of
Pab and the animals’ psychological
well-being (see Turner et al. [1997]
for one example).
8. Pathology of animals following Pab
production: It should be determined
whether there are pathological effects
that may be indicative of pain
and distress as a result of Pab
production techniques.
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Mab Production
In the 1990s, Mab production received a great
deal of attention and there has since been
an initiative to eliminate the use of animals
for Mab production. In 2000, the National
Institutes of Health issued a guidance notice
on this issue and indicated that institutions
should utilize the in vitro methods of Mab
production when possible instead of utilizing
the mouse ascites method, which involves
a great deal of pain and distress. In 1997,
surveys indicated that one-third of respondent
U.S. facilities were involved in Mab production,
and of those, 66% had one or more investigators
utilizing the ascites method and 36% utilized
the in vitro method (McArdle, 1997). Informal
surveys indicate that most institutions in
the United States have since changed to
the in vitro procedure (McArdle, 1997).
It has been determined that in vitro
methods have the potential for a 3–5%
failure rate (Institute for Laboratory Animal
Research, 1999); in these rare cases, the
mouse ascites method would have to be used.
Some workshop participants, however, believe
(based on experience) that the actual failure
rate may be lower than that reported.
The Office of Laboratory Animal Welfare
(OLAW) of the National Institutes of Health
requests that institutions prove that the in
vitro method has failed if the ascites method
is being used. The U.S. Food and Drug
Administration requires use of the in vitro
method, and the U.S. Department of
Agriculture is supportive of the initiative
to eliminate Mab production to the extent
possible, as well. According to one workshop
participant, business has also dramatically
increased for in vitro Mab production
companies—another sign that the use
of the in vitro method has increased.
Some European participants voiced
concern about the status of Mab production
in some European countries. One participant
who works at an institution in Europe
indicated that her institution requires a signed
statement indicating that the in vitro method
was unsuccessful before the in vivo method
is approved. Since the induction of this
requirement, most people have stopped
requesting the use of the mouse ascites
method at that institution.
12

It should be noted, however, that some
European countries, including the United
Kingdom, the Netherlands, Germany, and
Switzerland, have an official ban on ascites
production, unless it can be demonstrated
that in vitro production systems would not
suffice. One of the consequences is that in
vivo production may simply have shifted
elsewhere, as there have been specific
cases of this observed.
Due to the success of the initiative to
end the use of the mouse ascites method,
the participants did not devote additional
attention to this issue.
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Appendix I
List of participants
Vera Baumans (D.V.M., Ph.D.) is a
professor of Laboratory Animal Science
at the Karolinska Institute. Her interests
are housing, behavior, and welfare
of laboratory animals.
Kathleen Conlee (B.Sc.) is director of
Program Management for Animal Research
Issues and coordinates the Pain & Distress
Initiative for The HSUS. She worked with
captive nonhuman primates in a research
setting for several years before joining
The HSUS.
Wim A. de Leeuw (D.V.M.) has been a
Senior Veterinary Public Health Officer
for the Inspectorate for Health Protection
and Veterinary Public Health, Ministry
of Public Health in the Netherlands since
1992. Dr. de Leeuw was also involved in
the draft of the Dutch Code of Practice for
the immunization of laboratory animals
and the organization of an international
workshop on polyclonal antibody production
sponsored by the European Centre for
the Validation of Alternative Methods.
Coenraad Hendriksen (D.V.M., Ph.D.) is
an animal welfare officer and senior scientist
at the Netherlands Vaccine Institute (NVI)
and head of the Netherlands Centre for
Alternatives to Animal Use (NCA) of
Utrecht University.

The Humane Society of the United States

David Johnson (D.V.M.), a laboratory
animal veterinarian, is a scientific
advisor for Harlan, Inc.
John McArdle (Ph.D.) recently founded
the International Center for Alternatives
Resources. He was director of the Alternatives
Research and Development Foundation
for approximately 20 years. Dr. McArdle
was instrumental in the promotion of the
in vitro method of Mab production in
the United States.
David Morton (B.V.Sc., Ph.D.) is a laboratory
animal veterinarian and professor and head
of the Department of Biomedical Science
at the University of Birmingham, United
Kingdom. His research interests include
the welfare of animals, particularly the
recognition and assessment of animals’
pain, distress, and suffering during
their use in research and other areas.
Norm Peterson (D.V.M.) is an assistant
professor in the Department of Comparative
Medicine and a clinical veterinarian at Johns
Hopkins University. His research interests
include the development of improved and
alternative technologies in hybridoma and
Mab production. Dr. Peterson also coordinates
the Refinement Program Project at the Center
for Alternatives to Animal Testing (CAAT).
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Jon Richmond (M.D., Ph.D.) is a physiology
and medical graduate, currently employed
as Chief Inspector of the Animals (Scientific
Procedures) Inspectorate at the Home Office
in the United Kingdom.
Margaret Rose (Ph.D.) is an associate
professor at the University of New
South Wales and specializes
in laboratory animal care.

Andrew N. Rowan (Ph.D.) is executive
vice president, Operations, at The HSUS
and studied biochemistry for his doctorate
degree. He has authored numerous scientific
articles on animal research, alternatives,
ethics of animal research, animal control,
and human-animal interactions.
Harold Stills (D.V.M.) is director
of Laboratory Animal Resources
and professor of pathology at Wright
State University School of Medicine.

Founded in 1954, The Humane Society of the United States (HSUS) is the nation’s largest
animal protection organization, with more than eight-and-a-half million members and constituents.
The organization works to create a humane and sustainable world for all animals, including
people, through education, advocacy, and the promotion of respect and compassion. For more
information on The HSUS’s Pain and Distress Initiative, visit www.hsus.org/research.
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Appendix II
Antibody suppliers*
Websites with links
to various antibody
suppliers
The Antibody Resource Page
www.antibodyresource.com
Altweb Special Section
on Monoclonal Antibodies
http://altweb.jhsph.edu/topics/mabs/where.htm
Biocompare
www.biocompare.com
The Nature Biotechnology Directory
www.guide.nature.com
University of California Davis–Monoclonal
Antibody Resources
www.vetmed.ucdavis.edu/Animal_Alternatives/
biblio~1.htm

Individual suppliers
Biogenes
www.biogenes.de/frames/base_win.html
Phone: +49-030-6576-2396
Biotez
www.biotez.de/english/eestart.htm
Phone: +49-030-9489-3317

The Humane Society of the United States

Calbiochem
www.emdbiosciences.com/html/CBC/home.html
Phone: +1-800-854-3417
Charles River Laboratories
www.criver.com
Phone: +1-978-658-6000
Covance Research Products
www.crpinc.com
Phone: +1-800-345-4114
Harlan Bioproducts for Science
www.hbps.com
Phone: +1-317-894-7521
Lampire Biological Laboratories
www.lampire.com/custom.html
Phone: +1-215-795-2838
Pharmacia Biotech
www.amershambiosciences.com/aptrix/
upp01077.nsf/Content/na_homepage
Phone: +1-800-526-3593
Promega
www.promega.com
Phone: +1-608-274-4330

* Listing of specific companies in this appendix in no way
signifies endorsement of these companies by The HSUS.
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Appendix III
Immunisation
IMMUNISATION
User:
Sex:

Source:

Animal No.:

Species/Strain:

Issue No.:

Date:
Antigen
Adjuvant
(type)
Volume
per site
Route
Number
of sites
SIGNATURE
TEST BLEED
Date:
Site of
withdrawal
Volume
SIGNATURE
ANAESTHETIC/SEDATIVE
Type
Volume/dose
Site
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HEALTH AND WELFARE SCORE
User:
Sex:

Source:

Animal No.:

Species/Strain:

Issue No.:

Date:
Appearance
abnormal
Inactive
Starey coat
Huddling
Isolated
Eyes half closed
Hollow flanks
Not eating/
drinking
Bodyweight (g)
Group weight*
Average weight*
% Weight loss
Body temp
Injection site, e.g.,
abscess, ulceration
Other:
Action taken:
SIGNATURE
*Mice when immunized in groups. If an individual mouse is affected, it will be weighed separately.
Humane endpoints and actions:
1) Any animal showing departure from normal growth rates or other deterioration in condition, attributable to the procedure, will be
carefully monitored and killed if there is no response to treatment as soon as this becomes clear and always within 7 days.
2) Any animal showing signs of anaphylaxis will be killed immediately.
3) Any animal with confirmed anaemia will be rested until the problem is resolved, or if this is not possible, killed
and exsanguinated as soon as possible.
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